|

WX-0593 Tablets Clinical Trials

2 actively recruiting trials

Also known as: Iruplinalkib

Pipeline

Phase 2: 2

Top Sponsors

  • Pingping Song1
  • Jinming Yu1

Indications

  • Non-small Cell Lung Cancer (NSCLC)2
  • Lung Cancer2
  • Cancer2

Other2 trials

Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer
Phase 2
WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.